公司资料
AnaptysBio, Inc. 股价、新闻与催化剂
- 股票代码:
- ANAB
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
59.69 USD (+2.09%)
收盘价
最后更新: 2026年8月17日
1.49B USD
市值
股价为何变动
As of Aug 17, 2026, ANAB closed up 2.09% at $59.69. No new same-company headline was identified in the current news window.
公司概览
Biopharma Royalty Company
Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio.
Jemperli Economics
Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck cancers.
Imsidolimab Economics
The company also retains financial exposure to Vanda’s imsidolimab program in generalized pustular psoriasis.
未来催化剂
- Data from the pivotal AZUR-1 study of Jemperli in locally advanced rectal cancer are expected in the second half of 2026.
- Data from the Phase 2 AZUR-4 colon cancer study are expected in the fourth quarter of 2026.
- The FDA PDUFA action date for imsidolimab in generalized pustular psoriasis is December 12, 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。